Any Clinical Benefit From the Use of Oncofoetal Markers in the Management of Chemotherapy for Patients with Metastatic Colorectal Carcinomas?

This publication has 20 references indexed in Scilit:

• Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
  The Lancet, 2000
• Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
  British Journal of Cancer, 2000
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.
  Journal of Clinical Oncology, 1997
• The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer
  British Journal of Cancer, 1994
• Elevated CA19‐9 as the most significant prognostic factor in advanced colorectal carcinoma
  Journal of Surgical Oncology, 1992
• Liver and abdominal screening in patients with cancer: CT versus MR imaging.
  Radiology, 1988
• Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer.
  Gut, 1987
• Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
  Journal of Clinical Oncology, 1984
• CEA Monitoring of Palliative Treatment for Colorectal Carcinoma
  Annals of Surgery, 1977